Brief: Biosynex Upgrades Its 2020 Turnover Target
Dec 1 (Reuters) - BIOSYNEX SA ALBIO.PA :
* UPGRADES ITS OBJECTIVE IN 2020 TURNOVER WITH A RANGE
BETWEEN €
150 MILLION AND € 170 MILLION
* PLANS TO LAUNCH ITS CE CERTIFIED COVID-19 SEROLOGICAL
SELF-TEST
IN PHARMACIES IN SPAIN, ITALY AND BELGIUM FROM DECEMBER 2020
Further company coverage: ALBIO.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Biosynex SA
See all newsBrief: Biosynex FY Revenue Down To EUR 93.1 Million
Brief: Biosynex Announces Completion Of Merger-Absorption Of Theradiag
Brief: Biosynex Q3 Group Revenue Rises To EUR 24.4 Mln
Brief: Biosynex Announces Its Subsidiary Procisedx Acquires Two U.S. Patents
Brief: Biosynex's Procisedx Obtains First FDA Approvals